Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase | |
Dai, Xiaoyang5,6; Yan, Juan1,5; Fu, Xuhong5; Pan, Qiuming5; Sun, Danni5; Xu, Yuan2; Wang, Jiang3; Nie, Litong4; Tong, Linjiang5; Shen, Aijun5 | |
刊名 | CLINICAL CANCER RESEARCH |
2017-10-15 | |
卷号 | 23期号:20页码:6267-6278 |
ISSN号 | 1078-0432 |
DOI | 10.1158/1078-0432.CCR-17-0242 |
文献子类 | Article |
英文摘要 | Purpose: Recent epidemiological and clinical studies have suggested the benefit of aspirin for patients with cancer, which inspired increasing efforts to demonstrate the anticancer ability of aspirin and reveal the molecular mechanisms behind. Nevertheless, the anticancer activity and related mechanisms of aspirin remain largely unknown. This study aimed to confirm this observation, and more importantly, to investigate the potential target contributed to the anticancer of aspirin. Experimental Design: A homogeneous time-resolved fluorescence (HTRF) assay was used to examine the impact of aspirin on heparanase. Streptavidin pull-down, surface plasmon resonance (SPR) assay, and molecular docking were performed to identify heparanase as an aspirin-binding protein. Transwell, rat aortic rings, and chicken chorioallantoic membrane model were used to evaluate the antimetastasis and anti-angiogenesis effects of aspirin, and these phenotypes were tested in a B16F10 metastatic model, MDA-MB-231 metastatic model, and MDA-MB-435 xenograft model. Results: This study identified heparanase, an oncogenic extracellular matrix enzyme involved in cancer metastasis and angiogenesis, as a potential target of aspirin. We had discovered that aspirin directly binds to Glu225 region of heparanase and inhibits the enzymatic activity. Aspirin impeded tumor metastasis, angiogenesis, and growth in heparanase-dependent manner. Conclusions: In summary, this study has illustrated heparanase as a target of aspirin for the first time. It provides insights for a better understanding of the mechanisms of aspirin in anticancer effects, and offers a direction for the development of small-molecule inhibitors of heparanase. (C)2017 AACR. |
资助项目 | "Personalized Medicines-Molecular Signature-based Drug Discovery and Development," Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020000] ; NSFC-Shandong Joint Fund for Marine Science Research Centers[U1406402] ; Natural Science Foundation of China[81302791] ; Youth Innovation Promotion Association CAS[00000000] ; Shanghai Talent Development Funds[201663] ; Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020326] |
WOS关键词 | NONSTEROIDAL ANTIINFLAMMATORY DRUGS ; COLORECTAL-CANCER ; BREAST-CANCER ; COLON-CANCER ; INDUCED APOPTOSIS ; GROWTH-FACTOR ; CELLS ; RISK ; SULFATE ; SUPPRESSES |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | AMER ASSOC CANCER RESEARCH |
WOS记录号 | WOS:000413151000027 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/272447] |
专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
通讯作者 | Huang, Xun; Ding, Jian; Geng, Meiyu |
作者单位 | 1.Univ Chinese Acad Sci, Beijing, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, Key Lab Receptor Res, Shanghai, Peoples R China; 4.Chinese Acad Sci, Shanghai Inst Mat Med, Chem Prote Ctr, Shanghai, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai, Peoples R China; 6.Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou, Zhejiang, Peoples R China; |
推荐引用方式 GB/T 7714 | Dai, Xiaoyang,Yan, Juan,Fu, Xuhong,et al. Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase[J]. CLINICAL CANCER RESEARCH,2017,23(20):6267-6278. |
APA | Dai, Xiaoyang.,Yan, Juan.,Fu, Xuhong.,Pan, Qiuming.,Sun, Danni.,...&Geng, Meiyu.(2017).Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase.CLINICAL CANCER RESEARCH,23(20),6267-6278. |
MLA | Dai, Xiaoyang,et al."Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase".CLINICAL CANCER RESEARCH 23.20(2017):6267-6278. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论